Answers are grounded in this paper and cite their sources.
Case observations reveal genetic alterations impact therapy and prognosis for angiomatoid fibrous histiocytoma in adrenal locations, suggesting the need for molecular profiling.
Atypical-location AFH (e.g., adrenal) exhibits divergent pathologic phenotypes. Diagnosis requires integrated IHC/molecular analysis (e.g., EWSR1 status). Prognostic implications of genetic alterations (e.g., ALK expression) highlight the need for molecular profiling to guide therapy and prognosis.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: